TVGN Tevogen Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1860871 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY26.3%
TTM EPS YoY23.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-571.7%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets421.4%
Debt / equity—
Current ratio0.13x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.43x
Accruals ratio-325.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | — | — | — | — |
| R&D expense | $11.11M | $31.03M | $4.40M | — |
| SG&A expense | $15.03M | $22.53M | $4.44M | $953,083 |
| Operating income | -$26.14M | -$53.56M | -$8.84M | — |
| Interest expense | — | $184,037 | $1.21M | — |
| Income tax | $4,750 | $1,750 | — | — |
| Net income | -$26.28M | -$13.73M | -$60.48M | $4.41M |
| EBITDA | -$25.95M | -$53.40M | -$8.68M | — |
| EPS (basic) | -8.08 | -3.50 | -2.44 | — |
| EPS (diluted) | -8.08 | -3.50 | -2.44 | — |
| Weighted avg. shares (diluted) | 3.32M | 2.93M | 24.75M | — |
| Banking | ||||
| Net interest income | -$195,618 | -$184,037 | — | — |
| Balance sheet | ||||
| Cash & equivalents | $552,372 | $1.28M | $1.05M | $5.48M |
| Current assets | $1.54M | $2.36M | $1.72M | $274,356 |
| PP&E, net | $170,308 | $296,442 | $458,651 | — |
| Total assets | $4.38M | $3.46M | $5.51M | $357.14M |
| Current liabilities | $7.07M | $9.04M | $85.48M | $350,454 |
| Short-term debt | — | — | — | $0 |
| Total liabilities | $12.62M | $10.14M | $99.93M | $15.06M |
| Shareholders' equity | -$8.23M | -$6.67M | -$94.43M | -$33.95M |
| Shares outstanding | 4.02M | 3.56M | 120.00M | 2.38M |
| Cash flow statement | ||||
| Operating cash flow | -$12.33M | -$12.00M | -$8.17M | -$215,395 |
| Capital expenditure | $64,439 | — | $133,000 | — |
| Free cash flow | -$12.39M | — | -$8.30M | — |
| Investing cash flow | -$64,439 | — | -$133,000 | — |
| Financing cash flow | $11.66M | $12.23M | $3.87M | — |
| Depreciation & amortization | $190,573 | $162,209 | $163,300 | — |
| Stock-based compensation | $16.22M | $40.76M | — | — |
| Share buybacks | — | — | $342.98M | — |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.